Anti-Trastuzumab antibodies are immune system-generated antibodies directed against trastuzumab, a recombinant humanized monoclonal antibody that targets the HER-2 receptor. Trastuzumab is widely used in the treatment of HER-2 positive breast cancer and functions by blocking receptor signaling and mediating immune cell cytotoxicity. However, in some patients, the immune system can mount a response against the therapeutic antibody itself, leading to the formation of anti-drug antibodies (ADAs) such as anti-trastuzumab IgG. These ADAs can neutralize trastuzumab’s action or alter its pharmacokinetics, potentially reducing treatment efficacy or inducing adverse effects.
In a clinical setting, the detection and monitoring of anti-trastuzumab antibodies serve as an important component of therapeutic drug monitoring (TDM). TDM can help assess patient response, guide treatment decisions, and improve individualized dosing regimens. It can also identify patients at risk for reduced therapeutic benefit or increased risk of immune-mediated reactions. The presence of anti-trastuzumab antibodies may necessitate switching therapies or co-administering immunosuppressive agents to restore efficacy.
In research contexts, quantifying anti-trastuzumab levels provides insights into mechanisms of treatment resistance and immune responses in HER-2 positive cancers. Monitoring anti-trastuzumab antibodies helps improve biologic drug formulations, enhance safety profiles, and guide the development of next-generation HER-2 targeting therapies with reduced immunogenicity.
This product is manufactured in Turkey by Matriks Biotek.